MR imaging features of triple-negative breast cancers

Breast Journal

Volumn 19, Issue 6, 2013, Pages 643-649

  Sung, Janice S ^a   Jochelson, Maxine S ^a   Brennan, Sandra ^a   Joo, Sandra ^a   Wen, Yong H ^a   Moskowitz, Chaya ^b   Zheng, Junting ^b   Dershaw, D David ^a   Morris, Elizabeth A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Sibley Hospital   (United States)

Author keywords

breast cancer; MRI; TN; triple negative

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CLINICAL FEATURE; CONTRAST ENHANCEMENT; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE EVALUATION; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER; TUMOR NECROSIS; TUMOR VOLUME;

BREAST CANCER; MRI; TN; TRIPLE NEGATIVE;

ADULT; AGED; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84886801605     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12182     Document Type: Article

References (35)

1. Zaky SS, Lund M, May KA, et al,. The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy. Ann Surg Oncol 2011; 18: 2858-65.
2. Whitman GJ, Albarracin CT, Gonzalez-Angulo AM,. Triple-negative breast cancer: what the radiologist needs to know. Semin Roentgenol 2011; 46: 26-39.
3. Foulkes WD, Smith IE, Reis-Filho JS,. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-48.
4. Reis-Filho JS, Tutt AN,. Triple negative tumours: a critical review. Histopathology 2008; 52: 108-18.
5. Stockmans G, Deraedt K, Wildiers H, Moerman P, Paridaens R,. Triple-negative breast cancer. Curr Opin Oncol 2008; 20: 614-20.
6. Carey LA, Perou CM, Livasy CA, et al,. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-502.
7. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N,. Triple-negative breast cancer-current status and future directions. Ann Oncol 2009; 20: 1913-27.
8. Bertucci F, Finetti P, Cervera N, et al,. How basal are triple-negative breast cancers? Int J Cancer 2008; 123: 236-40.
9. Bartsch R, Ziebermayr R, Zielinski CC, Steger GG,. Triple-negative breast cancer. Wien Med Wochenschr 2010; 160: 174-81.
10. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V,. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109: 1721-8.
11. Morris GJ, Naidu S, Topham AK, et al,. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007; 110: 876-84.
12. Rakha EA, Reis-Filho JS, Ellis IO,. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26: 2568-81.
13. Sorlie T, Tibshirani R, Parker J, et al,. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100: 8418-23.
14. Yang WT, Dryden M, Broglio K, et al,. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat 2008; 111: 405-10.
15. Kojima Y, Tsunoda H,. Mammography and ultrasound features of triple-negative breast cancer. Breast Cancer 2011; 18: 146-51.
16. Dogan BE, Gonzalez-Angulo AM, Gilcrease M, Dryden MJ, Yang WT,. Multimodality imaging of triple receptor-negative tumors with mammography, ultrasound, and MRI. AJR Am J Roentgenol 2010; 194: 1160-6.
17. Ko ES, Lee BH, Kim HA, Noh WC, Kim MS, Lee SA,. Triple-negative breast cancer: correlation between imaging and pathological findings. Eur Radiol 2010; 20: 1111-7.
18. Uematsu T, Kasami M, Yuen S,. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology 2009; 250: 638-47.
19. Chen JH, Agrawal G, Feig B, et al,. Triple-negative breast cancer: MRI features in 29 patients. Ann Oncol 2007; 18: 2042-3.
20. Ikeda DM, Hylton NM, Kuhl CK, et al,. BI-RADS: Magnetic Resonance Imaging. In:, D'Orsi CJ, Mendelson EB, Ikeda DM, et al., eds. Breast Imaging Reporting and Data System: ACR BI-RADS-Breast Imaging Atlas. 1st edn. Reston, VA, American College of Radiology, 2003.
21. Sorlie T, Perou CM, Tibshirani R, et al,. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-74.
22. Perou CM, Sorlie T, Eisen MB, et al,. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
23. Blows FM, Driver KE, Schmidt MK, et al,. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010; 7: e1000279.
24. Prat A, Parker JS, Karginova O, et al,. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.
25. Schnall MD, Blume J, Bluemke DA, et al,. Diagnostic architectural and dynamic features at breast MR imaging: multicenter study. Radiology 2006; 238: 42-53.
26. Macura KJ, Ouwerkerk R, Jacobs MA, Bluemke DA,. Patterns of enhancement on breast MR images: interpretation and imaging pitfalls. Radiographics 2006; 26: 1719-34.
27. Schrading S, Kuhl CK,. Mammographic, US, and MR imaging phenotypes of familial breast cancer. Radiology 2008; 246: 58-70.
28. Tsuda H, Takarabe T, Hasegawa T, Murata T, Hirohashi S,. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. Hum Pathol 1999; 30: 1134-9.
29. Kuhl CK, Schmutzler RK, Leutner CC, et al,. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 2000; 215: 267-79.
30. Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S,. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 2000; 24: 197-202.
31. Maiorano E, Regan MM, Viale G, et al,. Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. Breast Cancer Res Treat 2010; 121: 211-8.
32. Livasy CA, Karaca G, Nanda R, et al,. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264-71.
33. Cheang MC, Voduc D, Bajdik C, et al,. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-76.
34. Dent R, Trudeau M, Pritchard KI, et al,. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13 (15 Pt 1): 4429-34.
35. Hernandez-Aya LF, Chavez-MacGregor M, Lei X, et al,. Nodal status and clinical outcomes in a large cohort of patients with triple negative breast cancer. J Clin Oncol 2011; 29: 2628-34.